deltatrials
Completed PHASE4 NCT00224315

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Sponsor: Central Institute of Mental Health, Mannheim

Conditions Schizophrenia, Schizoaffective Disorder
Interventions risperidone ziprasidone
Updated 5 times since 2017 Last updated: Jun 2, 2008 Started: Nov 30, 2003 Completion: Sep 30, 2006

Listed as NCT00224315, this PHASE4 trial focuses on Schizophrenia, Schizoaffective Disorder and remains completed. Sponsored by Central Institute of Mental Health, Mannheim, it has been updated 5 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Central Institute of Mental Health, Mannheim
Data source: Central Institute of Mental Health, Mannheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Mannheim, Germany